AUM is a global clinical-stage oncology company focused on advancing a pipeline of precision therapeutics designed to deploy multi-faceted inhibition strategies to reverse cancer resistance. AUM has pipeline of four distinct programs by leveraging its portfolio-driven strategy. AUM advances and grows a portfolio of innovative, early-stage oncology assets based on the latest scientific breakthroughs Specific areas of focus include immuno-oncology, Innate immunity to address significant unmet medical need, including paediatric and orphan cancers. The management team has an extensive track record of selecting distinctive early-stage assets, successfully exiting virtual biotech models, including a $145M USD virtual biotech model with Eisai Pharmaceuticals.